Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)
Close on Nov 17, 2026Market cap $43.60MP/E –Yield –
Xilio Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Xilio Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -34.1%. For fiscal 2025 it was -80.1%, against -918.0% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -80.1% | +838.0 |
| FY2024 | Dec 31, 2024 | -918.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -34.1% | +161.9 |
| Q1 FY2026 | Mar 31, 2026 | -75.3% | +377.4 |
| Q4 FY2025 | Dec 31, 2025 | 75.7% | +835.2 |
| Q3 FY2025 | Sep 30, 2025 | -85.4% | +534.1 |
| Q2 FY2025 | Jun 30, 2025 | -196.0% | +394.8 |
| Q1 FY2025 | Mar 31, 2025 | -452.7% | – |
| Q4 FY2024 | Dec 31, 2024 | -759.5% | – |
| Q3 FY2024 | Sep 30, 2024 | -619.5% | – |
| Q2 FY2024 | Jun 30, 2024 | -590.8% | – |
See a number that looks wrong?